CAS Insights^TM

Stay ahead of the latest scientific breakthroughs that are accelerating the landscape of innovation and will transform global science in 2024

Learn how digital transformation is reducing waste and creating new revenue streams for companies as they repurpose waste byproducts.

Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.

The pharma industry is tackling major drug discovery challenges in several new ways. Have they been successful?

In this article, we speak with Nicole Stobart, Jeff Wilson, and Mark Schmidt, about how CAS is using authority constructs to index biological molecules.

Pharmaceutical manufacturers are investigating ways to cultivate insights from dark formulations data, turning once-hidden knowledge into drug discoveries.

With the push towards increased sustainability, here are four ways coatings manufacturers are making use of renewable feedstock for their own products.

As the drug repurposing market grows, pharmaceutical manufacturers are investigating ways to cultivate insights from dark formulations data, turning once hidden insights into drug repurposing innovations.

Ozempic, Wegovy, and Mounjaro are part of a new class of semaglutides (GLP-1 receptor agonists) that help treat obesity and diabetes by regulating blood sugar and appetite.

Learn how photocatalysis can produce clean hydrogen from water and solar energy and why it is crucial for decarbonization.

CAS and Totus Medicines discuss how targeted covalent inhibitors are revolutionizing cancer treatments.

Single-walled carbon nanotubes have great potential in several industries from renewable energy to drug delivery.

Iddo Friedberg, an expert in protein function prediction, shares how current prediction models are performing and what current bottlenecks remain.

Covalent inhibitors were once avoided due to negative side effects, but new drugs have changed the landscape.

Drugs created with covalent inhibitors are becoming more popular than other types, owing to their unique mechanism of action.

More than 100 antibody-drug conjugates are in clinical trials. These therapeutics combine the targeting abilities of antibodies with the power of chemotherapy to change cancer treatment.

Since 2018, research interest in antibody-drug conjugates has increased exponentially, due to their potential in the fight against cancer.

CAS scientists discuss overlooked ideas that have yet to win a Nobel Prize. From OLEDs and MOFs to mRNA therapeutics and more, these ideas have reshaped science and technology.

Incomplete prior art searches and analyses can lead to costly mistakes, leaving innovations and the value of intellectual property open to huge risk.

Digital initiatives are transforming the chemical industry, allowing for faster innovation and a sustainable future.

Patentability assessments in scientific industries come with significant challenges due to their complexity. However, CAS has tools designed to address these issues.

CAS, Bayer, and Caltech explore how the gut-brain axis influences health from IBS to autism.

Strategies to unlock dark data in the pharmaceutical industry. Reveal data insights and accelerate innovation through digitization and knowledge management.

CAS, the LaJolla Institute for Immunology, and Avidity Biosciences explore the convergence of biology and chemistry in emerging therapeutics for cancer, vaccines, and more.

Digital initiatives are transforming the pharmaceutical industry, allowing for faster drug development and expanded treatment options.